Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF.

Blood Adv. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922.

2.

Physicochemical and sensory evolutions of the lactic goat cheese Picodon in relation to temperature and relative humidity used throughout ripening.

Leclercq-Perlat MN, Saint-Eve A, Le Jan E, Raynaud S, Morge S, Lefrileux Y, Picque D.

J Dairy Sci. 2019 Jun;102(6):5713-5725. doi: 10.3168/jds.2018-15958. Epub 2019 Apr 17.

PMID:
31005324
3.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
4.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

5.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
6.

L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients.

Bello E, Kerry J, Singh S, Yip BH, Kušec R, Killick S, Raynaud S, Boultwood J, Pellagatti A.

Haematologica. 2018 Nov;103(11):e496-e500. doi: 10.3324/haematol.2018.190447. Epub 2018 Jun 14. No abstract available.

7.

Selective recovery of RNAs from bacterial pathogens after their internalization by human host cells.

Raynaud S, Le Pabic H, Felden B.

Methods. 2018 Jul 1;143:4-11. doi: 10.1016/j.ymeth.2018.04.035. Epub 2018 Apr 27.

8.

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M.

Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.

PMID:
27856460
9.

Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.

Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J.

J Mol Diagn. 2017 Jan;19(1):92-98. doi: 10.1016/j.jmoldx.2016.08.006. Epub 2016 Nov 14.

PMID:
27855276
10.

Residual Isocyanates in Medical Devices and Products: A Qualitative and Quantitative Assessment.

Franklin G, Harari H, Ahsan S, Bello D, Sterling DA, Nedrelow J, Raynaud S, Biswas S, Liu Y.

Environ Health Insights. 2016 Oct 13;10:175-190. eCollection 2016.

11.

Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Eclache V, Lafage-Pochitaloff M, Lefebvre C, Penther D, Raynaud S, Tigaud I.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):525-534. Review.

12.

The N-terminal Part of Arabidopsis thaliana Starch Synthase 4 Determines the Localization and Activity of the Enzyme.

Raynaud S, Ragel P, Rojas T, Mérida Á.

J Biol Chem. 2016 May 13;291(20):10759-71. doi: 10.1074/jbc.M115.698332. Epub 2016 Mar 11.

13.

Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.

Huet S, Dulucq S, Chauveau A, Ménard A, Chomel JC, Maisonneuve H, Legros L, Perrin MC, Ferrant E, Moreilhon C, Couturier MA, Sujobert P, Magaud JP, Ugo V, Chabane K, Raynaud S, Hayette S; GBMHM (Groupe des Biologistes Moléculaires des Hémopathies Malignes, French Molecular Biology Group in Hematology).

Genes Chromosomes Cancer. 2015 Oct;54(10):595-605. doi: 10.1002/gcc.22263. Epub 2015 Aug 7.

PMID:
26252834
14.

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

Bello E, Pellagatti A, Shaw J, Mecucci C, Kušec R, Killick S, Giagounidis A, Raynaud S, Calasanz MJ, Fenaux P, Boultwood J.

Br J Haematol. 2015 Oct;171(2):210-214. doi: 10.1111/bjh.13563. Epub 2015 Jun 18.

15.

Starch synthase 4 is located in the thylakoid membrane and interacts with plastoglobule-associated proteins in Arabidopsis.

Gámez-Arjona FM, Raynaud S, Ragel P, Mérida A.

Plant J. 2014 Oct;80(2):305-16. doi: 10.1111/tpj.12633. Epub 2014 Sep 15.

16.

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.

Cluzeau T, Dubois A, Jacquel A, Luciano F, Renneville A, Preudhomme C, Karsenti JM, Mounier N, Rohrlich P, Raynaud S, Mari B, Robert G, Auberger P.

Oncotarget. 2014 Jun 30;5(12):4384-91.

17.

Arabidopsis thaliana plastoglobule-associated fibrillin 1a interacts with fibrillin 1b in vivo.

Gámez-Arjona FM, de la Concepción JC, Raynaud S, Mérida Á.

FEBS Lett. 2014 Aug 25;588(17):2800-4. doi: 10.1016/j.febslet.2014.06.024. Epub 2014 Jun 14.

18.

Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M.

PLoS One. 2014 Jan 9;9(1):e81843. doi: 10.1371/journal.pone.0081843. eCollection 2014.

19.

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.

Cluzeau T, Moreilhon C, Mounier N, Karsenti JM, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Auberger P, Fuzibet JG, Cassuto JP, Raynaud S.

Blood Cancer J. 2013 Nov 1;3:e155. doi: 10.1038/bcj.2013.52.

20.

Integrated genomic analysis of breast cancers.

Addou-Klouche L, Adélaïde J, Cornen S, Bekhouche I, Finetti P, Guille A, Sircoulomb F, Raynaud S, Bertucci F, Birnbaum D, Chaffanet M.

Balkan J Med Genet. 2012 Dec;15(Suppl):71-4. doi: 10.2478/v10034-012-0023-x.

21.

Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.

Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP.

Am J Hematol. 2013 Sep;88(9):780-3. doi: 10.1002/ajh.23509. Epub 2013 Jul 23.

22.

Genetic differences between Asian and Caucasian chronic lymphocytic leukemia.

Kawamata N, Moreilhon C, Saitoh T, Karasawa M, Bernstein BK, Sato-Otsubo A, Ogawa S, Raynaud S, Koeffler HP.

Int J Oncol. 2013 Aug;43(2):561-5. doi: 10.3892/ijo.2013.1966. Epub 2013 May 27.

23.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L.

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. No abstract available. Erratum in: Blood. 2014 Jun 26;123(26):4152.

PMID:
23243156
24.

Review of Shiga-toxin-producing Escherichia coli (STEC) and their significance in dairy production.

Farrokh C, Jordan K, Auvray F, Glass K, Oppegaard H, Raynaud S, Thevenot D, Condron R, De Reu K, Govaris A, Heggum K, Heyndrickx M, Hummerjohann J, Lindsay D, Miszczycha S, Moussiegt S, Verstraete K, Cerf O.

Int J Food Microbiol. 2013 Mar 15;162(2):190-212. doi: 10.1016/j.ijfoodmicro.2012.08.008. Epub 2012 Aug 14. Review.

PMID:
22939912
25.

Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks.

Kazimírová M, Mantel N, Raynaud S, Slovák M, Ustaniková K, Lang J, Guy B, Barban V, Labuda M.

Vector Borne Zoonotic Dis. 2012 Nov;12(11):979-85. doi: 10.1089/vbz.2011.0947. Epub 2012 Aug 27.

PMID:
22925017
26.

BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P.

Oncotarget. 2012 Apr;3(4):490-501.

27.

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P.

J Mol Cell Biol. 2012 Aug;4(4):207-20. doi: 10.1093/jmcb/mjs010. Epub 2012 Mar 31.

PMID:
22467682
28.

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.

Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P.

Oncotarget. 2011 Nov;2(11):874-85.

29.

Mechanism of action of the multikinase inhibitor Foretinib.

Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P.

Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1.

PMID:
22101270
30.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO).

Br J Haematol. 2012 Jan;156(1):76-88. doi: 10.1111/j.1365-2141.2011.08918.x. Epub 2011 Nov 3.

PMID:
22050763
31.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S, Wlodarska I, Michaux L, Roche-Lestienne C, Labis E, Taviaux S, Chapiro E, Nguyen-Khac F, Struski S, Dobbelstein S, Dastugue N, Lippert E, Speleman F, Van Roy N, De Weer A, Rack K, Talmant P, Richebourg S, Mugneret F, Tigaud I, Mozziconacci MJ, Laibe S, Nadal N, Terré C, Libouton JM, Decottignies A, Vikkula M, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO).

PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311. Epub 2011 Oct 21. Erratum in: PLoS One. 2011 Dec 13;6(12). doi: 10.1371/annotation/3b5aaa87-72b6-49d3-9ec9-f4a656e12e3a. Khac, Florence Nguyen [corrected to Nguyen-Khac, Florence].

32.

Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.

Impera L, Lonoce A, Fanfulla DA, Moreilhon C, Legros L, Raynaud S, Storlazzi CT.

Cancer Genet. 2011 Sep;204(9):512-5. doi: 10.1016/j.cancergen.2011.08.016.

PMID:
22018274
33.

Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression?

Micale L, Augello B, Daniele G, Macchia G, L'abbate A, Muehlematter D, Vandenberghe P, Johansson B, Cabrol C, Solé F, Dastugue N, Slovak ML, Lillington D, Raynaud S, Lafage M, Nacheva ED, Merla G, Storlazzi CT.

Blood Cells Mol Dis. 2011 Dec 15;47(4):259-61. doi: 10.1016/j.bcmd.2011.09.001. Epub 2011 Sep 25. No abstract available.

PMID:
21945030
34.

Kinome expression profiling and prognosis of basal breast cancers.

Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2011 Jul 21;10:86. doi: 10.1186/1476-4598-10-86.

35.

Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy.

Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, Auberger P.

Cell Cycle. 2011 Jul 15;10(14):2339-43. Epub 2011 Jul 15.

PMID:
21654192
36.

Enhancing the expression of starch synthase class IV results in increased levels of both transitory and long-term storage starch.

Gámez-Arjona FM, Li J, Raynaud S, Baroja-Fernández E, Muñoz FJ, Ovecka M, Ragel P, Bahaji A, Pozueta-Romero J, Mérida Á.

Plant Biotechnol J. 2011 Dec;9(9):1049-60. doi: 10.1111/j.1467-7652.2011.00626.x. Epub 2011 Jun 7.

37.

New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.

Cluzeau T, De Matteis M, Mounier N, Mannone L, Gratecos N, Ticchioni M, Thyss A, Raynaud S, Cassuto JP, Sirvent A.

Am J Hematol. 2011 Jul;86(7):619-21. doi: 10.1002/ajh.22029. Epub 2011 Apr 20. No abstract available.

38.

TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.

Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M; GOELAMS Investigators.

Haematologica. 2011 Jul;96(7):1059-63. doi: 10.3324/haematol.2011.040840. Epub 2011 Apr 20.

39.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.

PMID:
21494260
40.

Thyroxin overdose due to rheumatoid factor interferences in thyroid-stimulating hormone assays.

Georges A, Charrié A, Raynaud S, Lombard C, Corcuff JB.

Clin Chem Lab Med. 2011 May;49(5):873-5. doi: 10.1515/CCLM.2011.144. Epub 2011 Feb 9.

PMID:
21303295
41.

Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.

Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P.

Cancer Res. 2010 Dec 1;70(23):9659-70. doi: 10.1158/0008-5472.CAN-10-2034. Epub 2010 Nov 23.

42.

Genome profiling of ERBB2-amplified breast cancers.

Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.

BMC Cancer. 2010 Oct 8;10:539. doi: 10.1186/1471-2407-10-539.

43.

Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.

Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M, Figarella-Branger D.

Oncol Lett. 2010 Sep;1(5):883-884. Epub 2010 Sep 1.

44.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ.

BMC Cancer. 2010 Aug 2;10:401. doi: 10.1186/1471-2407-10-401.

45.

[Assessment of an immature platelet fraction (IFP%) in the diagnosis of thrombocytopenia].

Cannavo I, Ferrero-Vacher C, Sudaka I, Aquaronne D, Berthier F, Raynaud S.

Ann Biol Clin (Paris). 2010 Jul-Aug;68(4):415-20. doi: 10.1684/abc.2010.0449. French.

46.

CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia.

Guastadisegni MC, Lonoce A, Impera L, Di Terlizzi F, Fugazza G, Aliano S, Grasso R, Cluzeau T, Raynaud S, Rocchi M, Storlazzi CT.

Leukemia. 2010 Aug;24(8):1516-9. doi: 10.1038/leu.2010.106. Epub 2010 Jun 3. No abstract available.

PMID:
20520637
47.

Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.

Puissant A, Dufies M, Raynaud S, Cassuto JP, Auberger P.

Leukemia. 2010 May;24(5):1099-101. doi: 10.1038/leu.2010.55. Epub 2010 Apr 8. No abstract available.

PMID:
20376083
48.

Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.

Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, Auberger P.

Cancer Res. 2010 Feb 1;70(3):1042-52. doi: 10.1158/0008-5472.CAN-09-3537. Epub 2010 Jan 26.

49.

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP.

Blood. 2010 Apr 8;115(14):2882-90. doi: 10.1182/blood-2009-07-235119. Epub 2010 Jan 12.

50.

Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.

Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P.

Leukemia. 2010 Jan;24(1):115-24. doi: 10.1038/leu.2009.233. Epub 2009 Nov 19.

PMID:
19924144

Supplemental Content

Loading ...
Support Center